Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone
NCT ID: NCT02576912
Last Updated: 2023-08-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
38 participants
INTERVENTIONAL
2015-02-28
2019-06-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone: Sub-Study I
NCT02811939
Comparative Pharmacokinetic and Pharmacodynamic Effects of Delta-8 and Delta-9 THC
NCT05287256
The Effects of ∆-9-THC and Naloxone in Humans
NCT01591629
Cannabinoids, Neural Synchrony, and Information Processing
NCT00708994
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans
NCT02781519
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active Delta-9-THC and Placebo Pregnenolone
Active Delta-9-THC
Active Delta-9-THC (0.036 mg/kg) given intravenously.
Placebo
A placebo dose given sublingually.
Active Delta-9-THC and Active Pregnenolone
Active Delta-9-THC
Active Delta-9-THC (0.036 mg/kg) given intravenously.
Active Pregnenolone
A dose given sublingually.
Placebo Delta-9-THC and Active Pregnenolone
Active Pregnenolone
A dose given sublingually.
Placebo
Placebo dose given intravenously.
Placebo Delta-9-THC and Placebo Pregnenolone
Placebo
A placebo dose given sublingually.
Placebo
Placebo dose given intravenously.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Active Delta-9-THC
Active Delta-9-THC (0.036 mg/kg) given intravenously.
Active Pregnenolone
A dose given sublingually.
Placebo
A placebo dose given sublingually.
Placebo
Placebo dose given intravenously.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Individuals with a documented reaction/allergy to Pregnenolone
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yale University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Deepak C. D'Souza
Professor of Psychiatry
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Deepak C D'Souza, MD
Role: PRINCIPAL_INVESTIGATOR
Yale University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine
West Haven, Connecticut, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1501015242
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.